HUTCHMED (China) Ltd (FRA:H7T1)
€ 16.4 -0.7 (-4.09%) Market Cap: 2.80 Bil Enterprise Value: 2.13 Bil PE Ratio: 0 PB Ratio: 4.05 GF Score: 66/100
Back to the Transcripts List

Half Year 2024 HUTCHMED (China) Ltd Earnings Call Transcript

Jul 31, 2024 / 12:00PM GMT
Release Date Price: €16.5 (-0.60%)

Key Points

Positve
  • HUTCHMED (China) Ltd (HCM) reported a profit of $26 million in the first half of 2024, with oncology consolidated revenue reaching $168 million, on track to meet full-year guidance.
  • The company achieved strong in-market sales of FRUZAQLA in the US, reaching over $130 million, indicating robust early uptake.
  • HUTCHMED (China) Ltd (HCM) maintains a strong cash position of over $800 million, providing financial stability and flexibility for future investments.
  • The company is advancing its global strategy with the launch of fruquintinib worldwide and plans to file for US approval of savolitinib with AstraZeneca later this year.
  • The pipeline continues to grow with six NDAs or supplementary NDAs under review globally, including promising developments in gastric and endometrial cancer treatments.
Negative
  • Despite strong sales in the US, there is no updated sales guidance from Takeda for fruquintinib, creating uncertainty about future revenue expectations.
  • The regulatory approval process for fruquintinib in second-line gastric cancer in China is ongoing, with no clear timeline for approval.
  • R&D expenditures have been reduced due to strategic reorganization, which may impact the pace of development for some early-stage programs.
  • The competitive landscape in China remains fierce, posing challenges for maintaining market leadership and growth.
  • The company has not provided specific guidance on the quarterly sales trajectory for fruquintinib in Europe and Japan, pending reimbursement decisions.
David Ng;China;Ltd;Head;Weiguo Su;China;Ltd;Chief Executive Officer
HUTCHMED;Investor Relations & Capital Strategies;HUTCHMED;Chief Scientific Officer,

()- -

Hello, everyone. Welcome to HUTCHMED 2014 (sic - 2024) interim results presentation. My name is David Ng, Head of HUTCHMED IR. Our results announcement as well as our presentation slides have already been uploaded to our company homepage as well as the Hong Kong Stock Exchange website.

Before we star, just a few quick reminders. (Event Instructions) And finally, please read on page 2 of our presentation slides for the Safe Harbor statement and disclaimer. The performance and results of operation of the HUTCHMED contained within this presentation are historical in nature and past performance is no guarantee of future results.

So with no further delay, let me introduce our Chief Executive Officer and Chief Scientific Officer, Dr. Su, to begin our presentation for day. Dr. Su?

- ()

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.